Practical Model for Selecting a “Best Value” Biosimilar
The authors of recent paper developed a practical model to aid pharmacists and clinicians with the “best-value” biological selection process. This process involves three consecutive steps, which include identifying criteria to be used in decision-making, weighing the importance of each criterion, and developing a scoring system to evaluate biological candidates. Read more.

Capturing Chemotherapeutic Agent Compounding Errors Remotely
According to the literature, the incidence of medication errors involving chemotherapeutic agents ranges from 0.004% to 41.6%. This is concerning given the potential lethality of such errors. Measures to minimize or avoid medication errors can have a profound effect on patient safety. Read more.

Acute Kidney Injury Secondary to Vancomycin and Piperacillin/Tazobactam
Results of studies examining the occurrence of acute kidney injury from the concomitant administration of vancomycin and piperacillin/tazobactam have been mixed, with some demonstrating an increased risk of nephrotoxicity and others showing no evidence of harm. Numerous factors account for this finding. Read more.